Evidence map›Paper›PMID 28131001›Full record

ArticleJournal of inorganic biochemistry2017

Challenges encountered during development of Mn porphyrin-based, potent redox-active drug and superoxide dismutase mimic, MnTnBuOE-2-PyP

Zrinka Rajic, Artak Tovmasyan, Otávio L de Santana, Isabelle N Peixoto, Ivan Spasojevic, Silmar A do Monte, Elizete Ventura, Júlio S Rebouças, Ines Batinic-Haberle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inorganic biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. HOxidative medicine and cellular longevity · 2021
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Porphyrin-Based SOD Mimic MnTnBu OE -2-PyPJournal of the American Heart Association · 2018
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zrinka RajicDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Artak TovmasyanDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Otávio L de SantanaDepartamento de Química, CCEN, Universidade Federal da Paraiba, João Pessoa, PB 58051-900, Brazil.
Isabelle N PeixotoDepartamento de Química, CCEN, Universidade Federal da Paraiba, João Pessoa, PB 58051-900, Brazil.
Ivan SpasojevicDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA; Duke Cancer Institute, Pharmaceutical Research Shared Resource, PK/PD Core Laboratory, Durham, NC 27710, United States.
Silmar A do MonteDepartamento de Química, CCEN, Universidade Federal da Paraiba, João Pessoa, PB 58051-900, Brazil.
Elizete VenturaDepartamento de Química, CCEN, Universidade Federal da Paraiba, João Pessoa, PB 58051-900, Brazil.
Júlio S RebouçasDepartamento de Química, CCEN, Universidade Federal da Paraiba, João Pessoa, PB 58051-900, Brazil. Electronic address: jsreboucas2@gmail.com.
Ines Batinic-HaberleDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: ibatinic@duke.edu.

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Pilot Project for the DTMI CRA ProgramUL1RR024128 · NCRR · DUKE UNIVERSITY · PI CALIFF, ROBERT M · 2006 to 2010
$48.1M
Fe porphyrin-based Redox Modulator in Experimental Stroke OutcomeR03NS082704 · NINDS · DUKE UNIVERSITY · PI BATINIC-HABERLE, INES · 2013 to 2014
$156k
NCI NIH HHS P30 CA014236NCRR NIH HHS UL1 RR024128NINDS NIH HHS R03 NS082704
6 · The paper itself

Abstract

We disclose here the studies that preceded and guided the preparation of the metal-based, redox-active therapeutic Mn(III) meso-tetrakis(N-n-butoxyethylpyridyl)porphyrin, MnTnBuOE-2-PyP

Indexed as

BiomimeticsManganeseMetalloporphyrinsModels, MolecularOxidation-ReductionOxidative StressPorphyrinsSuperoxide DismutaseManganeseMetalloporphyrinsMn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrinPorphyrinsSuperoxide DismutaseAlkoxyalkyl tosylatesFP-15Mechanism of pyridyl nitrogen quaternizationMn N-alkoxyalkylpyridylporphyrinsMnTnBuOE-2-PyP(5+) (BMX-001)MnTTEG-2-PyP(5+)SOD mimics

Identifiers

PMID28131001
PMCPMC5893775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.